nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

24.07.2018 | Review – Clinical Oncology

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

verfasst von: Yiran Zhang, Meng Zhang, Yifei Jiang, Xiulian Li, Yanli He, Pengjiao Zeng, Zhihua Guo, Yajing Chang, Heng Luo, Yong Liu, Cui Hao, Hua Wang, Guoqing Zhang, Lijuan Zhang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lentinan is a polysaccharide extracted from Shiitake mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.

Methods

We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.

Results

The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [p < 0.001, 95% confidence interval (CI) 0.102–0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74–0.85) and no statistical heterogeneity was found among studies (I² = 11%).

Conclusion

Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.

Bai R (2010) Radiation and chemotherapy combined with lentinan to treat with non-small cell lung cancer with brain metastasis. Hebei Med J 32:2046–2047

Banin Hirata BK, Oda JMM, Losi Guembarovski R et al (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Mark 2014:1–12CrossRef

Bao L, Wang Y, Ma R et al (2015) Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells. Pak J Pharm Sci 28:1595–1600PubMed

Barrett SV (2010) Breast cancer. J R Coll Physicians Edinb 40:335–339CrossRef

Bekkering S, Blok BA, Joosten LA et al (2016) In vitro experimental model of trained innate immunity in human primary monocytes. Clin Vaccine Immunol 23:926–933CrossRef

Brown GD, Gordon S (2003) Fungal beta-glucans and mammalian immunity. Immunity 19:311–315CrossRef

Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118–129CrossRef

Chai M, Xiao Y (2005) Effect of lentinan in the treatment of advanced non-small cell lung cancer. J Med Forum 26:69–70

Chang X, Shao P, Huang X et al (2013) Clinical research on cisplatin combined lentinan in local therapy of malignant pleural effusion. New Med 44:840–842

Chen J, Raymond K (2008) Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag 4:1265–1272CrossRef

Chen J, Seviour R (2007) Medicinal importance of fungal β-(1 → 3), (1 → 6)-glucans. Mycol Res 111:635–652CrossRef

Chen Q, Peng H, Dong L et al (2016) Activation of the NRF2-ARE signalling pathway by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated cisplatin nephrotoxicity. Int immunopharmacol 36:1–8CrossRef

Cheng SC, Quintin J, Cramer RA et al (2014) mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345(6204):1250684CrossRef

Cheung NK, Modak S, Vickers A et al (2002) Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother CII 51:557–564PubMed

Chihara G, Maeda Y, Hamuro J et al (1969) Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 222:687–688CrossRef

Clynes RA, Towers TL, Presta LG et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446CrossRef

Dai X (2010) Observation on chemotherapy combined with lentinan to treat metaphase or terminal non-small cell lung cancer. J Clin Med Pract 14:73, 77

Dai D (2014) Recent and long-term effect and adverse reaction of lentinan combined with GP chemotherapy in the treatment of non-small cell lung cancer. Mod J Integr Tradit Chin West Med 23:1627–1628

Dai J, Wu W (1998) Regulatory effect of lentinan on immune functions of patients with lung cancer. Cancer Res Prev Treat 25:144–145

Deng M, Wang S, Liu Z (2010) One case of anaphylactic shock induced by lentinan injection. Chin J Drug Appl Monit 07:321–322

Ding N, Huang Z, Zhang Q et al (2012) Observation of clinical effect of lentinan and vinorelbine and cisplatin recombination on patients with advanced non-small cell lung cancer. Anhui Med J 33:681–683

Forman D, Ferlay J (2014) The global and regional burden of cancer. In: Stewart BW, Wild CP (eds) World cancer report 2014. International Agency for Research on Cancer, Lyon, p 16

Gordon M, Bihari B, Goosby E et al (1998) A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med 29:305–330PubMed

Hamy AS, Belin L, Bonsang-Kitzis H et al (2018) Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer 118:e14CrossRef

Han L, Li J, Liu Y (2012) A clinical observation of lentinan combined with GP regimen in patients with advanced non-small cell lung cancer. Her Med 31:1029–1032

He D, Li J, Chen Z (2015) Recent and long-term effect observation of lentinan combined with EP chemotherapy in the treatment of small cell lung cancer. J Huaihai Med 33:598–599

Hirsch FR, Franklin WA, Veve R et al (2002) HER2/neu expression in malignant lung tumors. Semin Oncol 29:51–58CrossRef

Ina K, Furuta R (2017) Complete response of metastatic gastric cancer to chemoimmunotherapy. Indian J Med Res 146:141CrossRef

Ina K, Furuta R, Kataoka T et al (2011) Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol 2:339–343CrossRef

Ina K, Kataoka T, Ando T (2013) The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem 13:681–688CrossRef

Jiang X, Zhou G (2009) Clinical research of combined lentinan for injection with chemotherapy on advanced non-small cell lung cancer. China Mod Dr 47:74–75

Jiang R, Tan X, Liu W et al (2010) Therapeutic effect of combined lentinan, gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Med J Qilu 25:132–134

Kay NE, LaPlant BR, Pettinger AM et al (2018) Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. Expert Rev Hematol 11:337–349CrossRef

Kupfahl C, Geginat G, Hof H (2006) Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection. Int Immunopharmacol 6:686–696CrossRef

Levine DB (2008) The Hospital for the Ruptured and Crippled: William Bradley Coley, third Surgeon-in-Chief 1925–1933. HSS J 4:1–9CrossRef

Li X (2001) Progress in anti-tumor drugs. China Pharm 12:429–431

Li Z, Zhu Y, Zhang P et al (2009) Clinical observation on GP chemotherapy combined with lentinan to treat advanced non-small cell lung cancer. J Pract Med 25:3480–3482

Li J, Song W, Wang S (2013) 30 cases of advanced non-small cell lung cancer treat with lentinan combined with GP chemotherapy. Guangdong Med J 34:1432–1434

Li C, Zhu T, Lu X (2016) Clinical analysis of the application of lentinus edodes polysaccharides combined with chemotherapy in the treatment of patients with advanced lung cancer. Mod Diagn Treat 27:1614–1616

Liu D, Qian J, Pu M (2003) Research status of anti-tumor effect of lentinan. Edible Fungi 2:6–7

Liu W, Gu J, Qi J et al (2015) Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. J Cell Mol Med 19:1949–1955CrossRef

Lu C (2013) Clinical observation on 26 cases of lung cancer with malignant pericardial effusion treated with lentinan and cisplatin. Guiding J Tradit Chin Med Pharm 19:53–54

Lu H, Hong S, Zhang X (2008) Clinical analysis of 63 cases with advanced non-small cell lung cancer treated with lentinan combined with NP chemotherapy. J XinJiang Med Univ 31:92–93

Lv G, Fan L, Zhang Z et al. (2009) Development of research on lentinan. Acta Agriculturae Zhejiangensis 21:183–188

Ma J (2014) Efficacy of lentinan combined with NP regimen in treatment of patients with advanced non-small cell lung cancer and its effect on immunologic function. Chin J Biochem Pharm 34:154–156

Makanjuola SB, Popoola AO, Oludara MA (2014) Radiation therapy: a major factor in the 5-year survival analysis of women with breast cancer in Lagos. Niger Radiother Oncol 111:321–326CrossRef

Murphy EA, Davis JM, Carmichael MD (2010) Immune modulating effects of beta-glucan. Curr Opin Clin Nutr Metab Care 13:656–661CrossRef

Nishitani Y, Zhang L, Yoshida M et al (2013) Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLoS One 8:e62441CrossRef

Novakovic B, Habibi E, Wang SY et al. (2016) β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167(5):1354–1368CrossRef

Peng X, Fan X, Shi X et al (2008) Influence of lentinan on expression of TLR4, TLR9 of mouse splenic T/B cells. Chin J Clin Pharmacol 24:234–236

Peng J, Zhang X, Chen C et al (2013) Nursing care of 3 cases of allergy caused by intravenous infusion of lentinan. Chin Gen Pract Nurs 11:1512

Peter G, Karoly V, Imre B et al (1988) Effects of lentinan on cytotoxic functions of human lymphocytes. Immunopharmacol Immunotoxicol 10:157–163CrossRef

Qian J (2010) 34 cases clinical observation of lentinan adjuvant therapy in the treatment of non-small cell lung cancer. Chin J Mod Drug Appl 04:114–115

Quintin J (2018) Fungal mediated innate immune memory, what have we learned? Semin Cell Dev Biol. https://doi.org/10.1016/j.semcdb.2018.05.023 CrossRefPubMed

Quintin J, Saeed S, Martens JHA et al (2012) Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12:223–232CrossRef

Ruthes AC, Smiderle FR, Iacomini M (2016) Mushroom heteropolysaccharides: a review on their sources, structure and biological effects. Carbohyd Polym 136:358–375CrossRef

Saitô H, Ohki T, Takasuka N et al (1977) A 13C-N.M.R.-Spectral study of a gel-forming, branched (1 → 3)-β-d-glucan, (lentinan) from Lentinus edodes, and its acid-degraded fractions. Structure, and dependence of conformation on the molecular weight. Carbohyd Res 58:293–305CrossRef

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346:92–98CrossRef

Shang S, Huang J (2009) Observation on short-term therapeutic and adverse effect of lentinan and vinorelbine and oxaliplatin in recombination on patients with advanced non-small cell lung cancer. Clin Focus 24:501–504

Shi X, Ding Q, Yang Q (2007) Lentinan combined with chemotherapy in the treatment of advanced non-small cell lung cancer. China Cancer 16:946–948

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235:177–182CrossRef

Song Q, Zhu J (2016) Effect of Mushroom polysaccharide injection on serum tumor markers and clinical effect in patients with stage III and IV SCLC. J China Prescr Drug 14:12–13

Surenjav U, Zhang L, Xu X et al (2006) Effects of molecular structure on antitumor activities of (1 → 3)-β-d-glucans from different Lentinus edodes. Carbohyd Polym 63:97–104CrossRef

The Top 10 Causes of Death (2018). http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 23 July 2018

Thomas AA, Brennan CW, DeAngelis LM et al (2014) Emerging therapies for glioblastoma. JAMA Neurol 71:1437–1444CrossRef

van Meir H, Nout RA, Welters MJ et al (2017) Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology 6:e1267095CrossRef

Wang J (1994) Clinical observation of lentinan in treatment of 60 cases of hepatitis B. J Chin Med 16:23–24

Wang W, Dai X, Ouyang X (2006) Efficacy of lentinan combined with chemotherapy in advanced non-small cell lung cancer. China J Lung Cancer 09:78–81

Wang G, Lin W, Zhao R et al (2008) Effects of six polysaccharides extracted from plants on the immunological cells of mice. J Hyg Res 37:577–580

Wang J, Dong S, Liu C et al (2010) β-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen. J Biomed Biotechnol 2010:645213PubMedPubMedCentral

Wang J, Zhang Y, Zhao H (2011) The influence of immune functions and therapeutic and adverse effect of lentinan combined with chemotherapy in advanced non-small cell lung cancer. Natl Med Front China 06:15–17

Wang JL, Bi Z, Zou JW et al (2012) Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol Med Rep 5:745–748CrossRef

Wang Y, Han X, Li YD et al (2015) Effects of tumor-specific antigen induced by lentinan on murine H22 hepatocellular carcinoma immunoprophylaxis. Eur Rev Med Pharmacol Sci 19:4516–4524PubMed

Wang P, Zhao S, Yang B et al (2016) Anti-diabetic polysaccharides from natural sources: a review. Carbohyd Polym 148:86–97CrossRef

Wei Y, Xie M (2015) The influence of lentinan injection on curative effect and quality life of patients with medium and advanced lung cancer after chemotherapy. Guiding J Tradit Chin Med Pharm 21:25–27

Wu X (2009) Clinical observation on advanced non-small cell lung cancer in the old treated with lentinan combined with NVB and DDP. China Foreign Med Treat 28:76–77

Wu X (2015) Clinical analysis of lentinan combined with chemotherapy in treatment of advanced lung cancer. Chin Arch Tradit Chin Med 27:456–458

Wu B, Zhang Y, Zhang L (1993) III clinical trial summary of lentinan in the treatment of 108 cases with chronic viral hepatitis. Fujian J Tradit Chin Med 24:10–13, 50

Xiao X, Liu C, Yuan X et al (2015) Clinical effect of lentinan combined with DP chemotherapy on middle-late stage non-small cell lung cancer. Pract J Card Cereb Pneumal Vasc Dis 23:91–93

Xie Z, Xie J, Wen J et al (2006) A comparison between TP regimen with lentinan and with megestrol acetate for advanced non-small cell lung cancer. China Cancer 15:199–202

Xin W, Shi L, Zhou Y (2016) Efficacy of lentinan combined with NP chemotherapy in treatment of patients with advanced non-small cell lung cancer and its effect on immunologic function. Mod J Integr Tradit Chin West Med 25:3349–3351

Xu X, Pan C, Zhang L et al (2011) Immunomodulatory beta-glucan from Lentinus edodes activates mitogen-activated protein kinases and nuclear factor-kappaB in murine RAW 264.7 macrophages. J Biol Chem 286:31194–31198CrossRef

Yin H, Yang G (2016) Efficacy of synergistic combination of lentinan and GP regimen in stage IV lung squamous cell carcinoma. Oncol Prog 14:687–689

Yoshino S, Tabata T, Hazama S et al (2000) Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 20:4707–4711PubMed

Yoshino S, Yoshida S, Maeda N et al (2010) Clinical evaluation of the combination treatment of intrapleural or intraperitoneal administration of lentinan and OK-432 for malignant effusion. Gan to kagaku ryoho. Cancer Chemother 37:2798–2800

Yue F, Jia T (2010) Clinical observation of lentinan combined with paclitaxel liposome on advanced non-small cell lung cancer. Pract J Card Cereb Pneumal Vasc Dis 18:1791–1792

Zhang H (2016) Clinical analysis of lentinan combined with chemotherapy for elderly patients with advanced non-small cell lung cancer. Shenzhen J Integr Tradit Chin West Med 26:44–45

Zhang H, Xu J, Ren S (2009) Lentinan combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chin J Cancer Biother 16:523–525

Zhang C, Xie C, Kang Z et al (2014) Clinical observation on GP chemotherapy combined with lentinan to treat metaphase or terminal non-small cell lung cancer. J Qiqihar Univ Med 35:164–165

Zhang Y, Li Q, Shu Y et al (2015a) Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway. J Funct Foods 15:151–159CrossRef

Zhang Y, Yu J, Xiang Y et al (2015b) Clinical efficacy and safety of lentinan combined with chemotherapy for elderly patients with advanced non-small cell lung cancer. Antitumor Pharm 03:222–225

Zhao L (2012) A clinical study on non-small cell lung cancer therapy by combination of lentinan with chemotherapy. Anhui Med Pharm J 16:1496–1497

Zhao X, Ma L (2011) Toxicity-reducing and efficacy-enhancing action of lentinan with chemotherapy in the treatment of advanced non-small cell lung cancer. Clin Ration Drug Use 04:20–21

Zhao C, Li X, Wang Z et al (2011) Immune function and effect of concurrent chemoradiotherapy combined lentinan on patients with advanced non-small cell lung cancer. Anhui Med Pharm J 15:1431–1433

Zhao W, Chen D, Chen J (2013) Curative effect and adverse reaction of lentinan combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer. Chin J Clin Pharmacol Ther 18:71–77

Zheng H, Zeltsman M, Zauderer MG et al (2017) Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 9:913–927CrossRef

Zhou C, Liu M (2010) 30 cases of adverse reaction caused by lentinan. Zhejiang J Integr Tradit Chin West Med 20:635

Zhou Z, Han Z, Zeng Y et al (2014) Chinese FDA approved fungal glycan-based drugs: an overview of structures, mechanisms and clinical related studies. Transl Med 04:1000141

Zhu Y, Zhang L (2013) Short-term curative effect of lentinan combined with chemotherapy in the treatment of lung cancer and its evaluation of immune function. China Pract Med 08:156–157

Titel: Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China
verfasst von: Yiran Zhang
Meng Zhang
Yifei Jiang
Xiulian Li
Yanli He
Pengjiao Zeng
Zhihua Guo
Yajing Chang
Heng Luo
Yong Liu
Cui Hao
Hua Wang
Guoqing Zhang
Lijuan Zhang
Publikationsdatum: 24.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2718-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)

Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment

Correction to: The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage endometrial cancer

The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie